Microbiome’s Moment Approaches: Finch Joins Rival C Diff Companies

Infection Is Common Killer

After a trial failure in 2016, four rival companies could produce pivotal data this year

FINCH

After setbacks in recent times, 2020 could be the year that the first microbiome-based therapy is approved by the US Food and Drug Administration.

A handful of companies are developing new oral therapies containing a controlled formulation of “gut friendly” live bacteria, with the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip